TY - JOUR

T1 - Calcium electroporation for recurrent head and neck cancer

T2 - A clinical phase I study

AU - Plaschke, Christina Caroline

AU - Gehl, Julie

AU - Johannesen, Helle Hjorth

AU - Fischer, Barbara Malene

AU - Kjaer, Andreas

AU - Lomholt, Anne Fog

AU - Wessel, Irene

PY - 2019/2

Y1 - 2019/2

N2 - Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca2+, ECG, and pain scores. Tumor response was measured on PET/MRI scans.Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post-treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.Level of Evidence: Level 4.

AB - Background: Calcium electroporation is a novel cancer treatment, which combines temporary cell permeability from electroporation with a high influx of calcium intracellularly resulting in cancer cell necrosis.Methods: A phase I trial performing calcium electroporation on 6 patients suffering from recurrent head and neck cancer. In general anesthesia, intratumoral calcium injections were followed by electroporation. Safety was monitored by adverse events registration, serum Ca2+, ECG, and pain scores. Tumor response was measured on PET/MRI scans.Results: Procedures were performed without complications. No serious adverse events, signs of hypercalcemia, or cardiac arrhythmias were observed. Two months post-treatment tumor responses on MRI: three partial responses, one stable disease, and two progression. Responses on PET: one partial metabolic disease, four with stable metabolic disease, and one not evaluable. One patient was without clinical evidence of disease after 12 months of observation.Conclusion: Calcium electroporation is feasible and safe in head and neck tumors. Clinical responses were observed in three of six patients, warranting further studies.Level of Evidence: Level 4.

U2 - 10.1002/lio2.233

DO - 10.1002/lio2.233

M3 - Journal article

C2 - 30828619

VL - 4

SP - 49

EP - 56

JO - Laryngoscope investigative otolaryngology

JF - Laryngoscope investigative otolaryngology

SN - 2378-8039

IS - 1

ER -